{"id":389143,"date":"2023-11-07T00:00:00","date_gmt":"2023-11-07T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0008-2023-biopharma-prostate-cancer-disease-landscape-forecast-g7-2023\/"},"modified":"2026-03-31T10:31:52","modified_gmt":"2026-03-31T10:31:52","slug":"dlsfon0008-2023-biopharma-prostate-cancer-disease-landscape-forecast-g7-2023","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0008-2023-biopharma-prostate-cancer-disease-landscape-forecast-g7-2023\/","title":{"rendered":"Prostate Cancer | Disease Landscape &#038; Forecast | G7 | 2023"},"content":{"rendered":"<p>Hormonal agents dominate the treatment landscape for prostate cancer and are routinely used in all lines of therapy. Next-generation hormonal treatment has expanded beyond metastatic castrate-resistant prostate cancer (mCRPC), impacting current treatment of nonmetastatic CRPC and metastatic hormone-sensitive prostate cancer (HSPC). Continued development of the hormonal therapies, plus the development of targeted agents (e.g., Janssen \/ GlaxoSmithKline\u2019s Zejula, Pfizer\u2019s Talzenna), antibody-drug conjugates (MacroGenics\u2019 vobramitamab duocarmazine), and novel prostate-specific membrane antigen (PSMA)-targeted radioligands (e.g., Novartis\u2019s Pluvicto and POINT Biopharma\u2019s 177Lu-PNT2002) will drive robust market growth over the 2022-2032 forecast period.<\/p>\n<p>QUESTIONS ANSWERED<\/p>\n<ul>\n<li>What are the sizes of the clinically and commercially relevant drug-treatable prostate cancer populations, and how will drug-treatment rates change over time?<\/li>\n<li>What are the key drivers and constraints in the prostate cancer market, and how will the major markets evolve over the 10-year forecast period?<\/li>\n<li>What is the current state of treatment for prostate cancer? What are interviewed experts\u2019 insights on these treatment options?<\/li>\n<li>What is the clinical and commercial potential of late-phase pipeline products, and what will be their likely positioning and uptake in the market?<\/li>\n<\/ul>\n<p>PRODUCT DESCRIPTION<\/p>\n<p>Disease Landscape &#038; Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p>SOLUTION ENHANCEMENT<\/p>\n<p>Disease Landscape &#038; Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.<\/p>\n<p>Disease Landscape &#038; Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.<\/p>\n","protected":false},"template":"","class_list":["post-389143","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-prostate-cancer","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389143","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389143\/revisions"}],"predecessor-version":[{"id":576052,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389143\/revisions\/576052"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389143"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}